Interview with Mark Henrick of the Nimbin Mardi-Grass and Hemp Embassy. Henrick discusses the state of the movement in Australia, the cure of basil cell carcinoma using a topical cannabis application, and the work of Tony Bower, and aboriginal medicine man.
New Jersey’s medical marijuana law, by excluding pain and psychiatric conditions, will impact about 4% of New Jersey’s medical marijuana patients. In other words, about 96% of New Jersey’s medical marijuana patients got screwed. That is a crushing defeat.
In 2001, according to Hollywood today the ten largest pharmaceutical companies in the Fortune 500 had profits in excess of the other 490 companies, the majority of this profit being from the SSRIs and the SNRIs.
The average net return for these ten pharmaceutical companies was 18.5% of sales, 16.3% of assets, and 33.2% of shareholders’ equity. The median net return for all other 490 industries in the Fortune 500 was only 3.3% of sales.
Even though about 30% of medical marijuana patients in California use it for depression and other psychiatric conditions, no other state has approved the use of cannabis for depression. In 1998 JAMA published a study which announced that pharmaceuticals, as prescribed, were the fourth leading cause of death in America.